"Complete response" trang 1 - tải miễn phí từ tailieunhanh
Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer

Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer
10    47    1
A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer

A nomogram for predicting pathological complete response in patients with human epidermal growth factor receptor 2 negative breast cancer
9    47    1
Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy

Pretreatment systemic inflammation response index is predictive of pathological complete response in patients with breast cancer receiving neoadjuvant chemotherapy
8    64    1
Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: A multicenter study

Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: A multicenter study
12    6    1
Predictive factors of disease-free survival after complete pathological response to neoadjuvant radiotherapy for rectal adenocarcinoma: Retrospective case series

Predictive factors of disease-free survival after complete pathological response to neoadjuvant radiotherapy for rectal adenocarcinoma: Retrospective case series
7    94    0
Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response

Prognostic assessment of breast carcinoma submitted to neoadjuvant chemotherapy with pathological non-complete response
12    97    0
Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: A lesion-based and patient-based analysis

Long-term outcomes and recurrence pattern of 18F-FDG PET-CT complete metabolic response in the first-line treatment of metastatic colorectal cancer: A lesion-based and patient-based analysis
10    91    0
Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer

Body mass index modifies the relationship between γ-H2AX, a DNA damage biomarker, and pathological complete response in triple-negative breast cancer
8    79    2
MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2- positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy

MET and PTEN gene copy numbers and Ki-67 protein expression associate with pathologic complete response in ERBB2- positive breast carcinoma patients treated with neoadjuvant trastuzumab-based therapy
11    55    1
Prolonged complete response after treatment withdrawal in HER2-overexpressed, hormone receptor-negative breast cancer with liver metastases: The prospect of disappearance of an incurable disease

Prolonged complete response after treatment withdrawal in HER2-overexpressed, hormone receptor-negative breast cancer with liver metastases: The prospect of disappearance of an incurable disease
5    54    1
A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): Rationale and design

A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): Rationale and design
8    48    1
Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: A large, multicenter, observational study

Response to neoadjuvant chemotherapy based on pathologic complete response in very young patients with ER-positive breast cancer: A large, multicenter, observational study
11    49    1
Survival landscape of different tumor regression grades and pathologic complete response in rectal cancer after neoadjuvant therapy based on reconstructed individual patient data

Survival landscape of different tumor regression grades and pathologic complete response in rectal cancer after neoadjuvant therapy based on reconstructed individual patient data
11    41    1
A nomogram based on platelet-tolymphocyte ratio for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy

A nomogram based on platelet-tolymphocyte ratio for predicting pathological complete response of breast cancer after neoadjuvant chemotherapy
9    2    1
Develop and validate a radiomics space-time model to predict the pathological complete response in patients undergoing neoadjuvant treatment of rectal cancer: An artificial intelligence model study based on machine learning

Develop and validate a radiomics space-time model to predict the pathological complete response in patients undergoing neoadjuvant treatment of rectal cancer: An artificial intelligence model study based on machine learning
11    7    1
Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: A case report

Confirmed complete response to nivolumab for advanced gastric cancer with peritoneal dissemination: A case report
6    25    1
CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy

CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy
11    66    0
Organ Preservation in Rectal Adenocarcinoma: A phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management

Organ Preservation in Rectal Adenocarcinoma: A phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management
13    86    1
Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk (“ugly”) locally advanced rectal cancer: Study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)

Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk (“ugly”) locally advanced rectal cancer: Study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT)
11    28    1
Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review

Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review
8    37    1